Aurinia Pharmaceuticals (AUPH) Cost of Revenue (2021 - 2026)

Aurinia Pharmaceuticals has reported Cost of Revenue for 6 years, with the latest figure at $6.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 24.13% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $30.6 million (up 5.25% YoY), and the FY2025 full-year result was $32.7 million, up 15.64% from the prior year.
• Cost of Revenue for Q1 2026 stood at $6.5 million, down from $8.8 million in the prior quarter.
• The five-year high for Cost of Revenue was $8.9 million in Q2 2024, with the low at $256000.0 in Q1 2022.
• Historically, Cost of Revenue has averaged $5.1 million across 5 years, with a median of $6.0 million in 2024.
• Annual changes were most pronounced in 2024 — Cost of Revenue soared 1741.33% — and 2026, when it slipped 24.13%.
• Aurinia Pharmaceuticals' Cost of Revenue stood at $1.4 million in 2022, then jumped by 296.11% to $5.4 million in 2023, then rose by 2.91% to $5.6 million in 2024, then soared by 58.48% to $8.8 million in 2025, then decreased by 26.07% to $6.5 million in 2026.
• The last three Cost of Revenue figures came in at $6.5 million (Q1 2026), $8.8 million (Q4 2025), and $8.2 million (Q3 2025), per Business Quant data.